GeneNovate Investors' Day

Overview

• Background

  The importance of gene and cell therapies as well as tissue therapeutics (Advanced Therapy Medicinal Products) is steadily increasing worldwide. In particular, patients with rare diseases - at least affecting 4 million people in Germany - and otherwise untreatable cancer patients can benefit from treatment in the long term. Technological advances, such as the expansion of the use of artificial intelligence, are further dynamizing the field.

  Sixteen gene therapies and one cell therapy are currently approved in Europe (as of December 2024, vfa). The number of clinical trials worldwide is constantly increasing. Groundbreaking developments are on the horizon for this innovative business field, with sales of up to EUR 27.9 billion expected by 2026. The German government has also recognized the potential of these innovative therapies. In a National Strategy for Gene- and Cell-Based Therapies, concrete measures have been defined to improve the framework conditions, e.g. in research and development, regulation or manufacturing practice.  One initiative is the GeneNovate Entrepreneurship Programme in the field of gene and cell therapies, which, for the second time in 2025, prepares participants from research and science who are interested in founding a company for the topic of spin-offs from the academic environment and accompanies them for six months. Bringing together different stakeholders is another key pillar of the strategy to facilitate the dialogue across disciplinary, sectoral, regional and national boundaries and thus accelerates translation.

  This is where the GeneNovate Investors' Day comes in: without smart investments and relevant expert mentoring, no new therapies! GeneNovate Investors' Day is a networking event for scientific, translationally oriented project teams, international startups, investors and experts from science, industry and politics. Discover with us the latest developments in the field of gene and cell therapies and promising investment opportunities.  Find out more in exciting panels on key topics such as the particular features of the value chain, investment specifics or international best practices. In the heart of Berlin, we create the right atmosphere for personal exchange!

• Overview Programme June 26-27, 2025

  Overview Dates

  • June 26: Final event of the GeneNovate Entrepreneurship Programme with focus on innovations in the field of Gene and Cell Therapies
    Location: Akademie der Künste, Berlin
  • June 26: Exclusive Evening Reception
    Location: French Embassy, Berlin | by invitation only
    In cooperation with French Embassy in Berlin and Stiftung Charité
  • June 27: Parliamentary Breakfast
    Location: Käfer Restaurant im Bundestag, Berlin | by invitation only
    In cooperation with Bio Deutschland and Thermo Fisher Scientific

  • June 27: GeneNovate Investors' Day
    Location: Akademie der Künste, Berlin
    This event is supported by the following partners: 
    Berlin Partner & HealthCapital, BPI, cytiva, , Nuvisan, Terumo Blood and Cell Technologies, Thermo Fisher & vfa.

     

• Partners & Sponsors

  

  If you are interested in becoming a sponsor or partner of the event, there are various opportunities available to you. This proposal includes a selection of package options to choose from.

  This event is supported by the following partners: 
  Bayer Co.Lab, Berlin Center for Gene and Cell Therapies, Berlin Partner & HealthCapital, BIO Deutschland, BPI, Cytiva, Gilead/Kite, Nuvisan, Terumo Blood and Cell Technologies, Thermo Fisher Scientific & vfa.

• Advisory Board

  

  The Board advises the Berlin Institute of Health on program design, the selection of startups and acts as a multiplier. Learn more about the members of the Advisory Board here.